



Pharmesis International Ltd.
5 Kallang Sector
#03-02
Singapore 349279
Company registration no.: 200309641E

**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS
FOR FOURTH QUARTER AND FULL YEAR ENDED 31 DECEMBER 2019**

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited financial results for the fourth quarter (“**4QFY2019**”) and the full year ended 31 December 2019 (“**FY2019**”), the Board would like to advise that the Group is expected to report a net loss for 4QFY2019 and FY2019.

Further details of the Group’s financial performance will be disclosed when the Company announces its unaudited financial results for 4QFY2019 and FY2019.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
21 February 2020